TY - JOUR
T1 - Medications and Impaired Driving
AU - Hetland, Amanda
AU - Carr, David B.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Amanda Hetland, NIH and NCATS. David B. Carr, MD, NIH, Office of Highway Safety in the Missouri Division of Traffic and Highway Safety, Pfizer, Janssen, Novartis, Medscape, AMA, ADEPT, and TIRF. This publication was made possible by Grant Number UL1 TR000448 and TL1 TR000449 from the National Center for Advancing Translational Sciences, National Institutes of Health. This work was also supported in part by the Office of Highway Safety in the Missouri Division of Traffic and Highway Safety and the Washington University Alzheimer’s Disease Research Center (P50AG05681, Morris PI). The authors report no conflicts of interest in relation to the content of this article.
PY - 2014/4
Y1 - 2014/4
N2 - Objective: To describe the association of specific medication classes with driving outcomes and provide clinical recommendations. Data Sources: The MEDLINE and EMBASE databases were searched for articles published from January 1973 to June 2013 on classes of medications associated with driving impairment. The search included outcome terms such as automobile driving, motor vehicle crash, driving simulator, and road tests. Study Selection and Data Extraction: Only English-language articles that contained findings from observational or interventional designs with ≥ 10 participants were included in this review. Cross-sectional studies, case series, and case reports were excluded. Data Synthesis: Driving is an important task and activity for the majority of adults. Some commonly prescribed medications have been associated with driving impairment measured by road performance, driving simulation, and/or motor vehicle crashes. This review of 30 studies identified findings with barbiturates, benzodiazepines, hypnotics, antidepressants, opioid and nonsteroidal analgesics, anticonvulsants, antipsychotics, antiparkinsonian agents, skeletal muscle relaxants, antihistamines, anticholinergic medications, and hypoglycemic agents. Additional studies of medication impact on sedation, sleep latency, and psychomotor function, as well as the role of alcohol, are also discussed. Conclusions: Psychotropic agents and those with central nervous system side effects were associated with measures of impaired driving performance. It is difficult to determine if such associations are actually a result of medication use or the medical diagnosis itself. Regardless, clinicians should be aware of the increased risk of impaired driving with specific classes of medications, educate their patients, and/or consider safer alternatives.
AB - Objective: To describe the association of specific medication classes with driving outcomes and provide clinical recommendations. Data Sources: The MEDLINE and EMBASE databases were searched for articles published from January 1973 to June 2013 on classes of medications associated with driving impairment. The search included outcome terms such as automobile driving, motor vehicle crash, driving simulator, and road tests. Study Selection and Data Extraction: Only English-language articles that contained findings from observational or interventional designs with ≥ 10 participants were included in this review. Cross-sectional studies, case series, and case reports were excluded. Data Synthesis: Driving is an important task and activity for the majority of adults. Some commonly prescribed medications have been associated with driving impairment measured by road performance, driving simulation, and/or motor vehicle crashes. This review of 30 studies identified findings with barbiturates, benzodiazepines, hypnotics, antidepressants, opioid and nonsteroidal analgesics, anticonvulsants, antipsychotics, antiparkinsonian agents, skeletal muscle relaxants, antihistamines, anticholinergic medications, and hypoglycemic agents. Additional studies of medication impact on sedation, sleep latency, and psychomotor function, as well as the role of alcohol, are also discussed. Conclusions: Psychotropic agents and those with central nervous system side effects were associated with measures of impaired driving performance. It is difficult to determine if such associations are actually a result of medication use or the medical diagnosis itself. Regardless, clinicians should be aware of the increased risk of impaired driving with specific classes of medications, educate their patients, and/or consider safer alternatives.
KW - automobile driving
KW - driving safety
KW - drugs and driving
KW - medication safety
KW - potentially driver-impairing medications
UR - http://www.scopus.com/inward/record.url?scp=84898678919&partnerID=8YFLogxK
U2 - 10.1177/1060028014520882
DO - 10.1177/1060028014520882
M3 - Review article
C2 - 24473486
AN - SCOPUS:84898678919
SN - 1060-0280
VL - 48
SP - 494
EP - 506
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
IS - 4
ER -